Cogent Biosciences (COGT) risk factors, FY2025 10-K

Risks Related to our Business

1. 01Our business is highly dependent on the success of our bezuclastinib program and our ability to discover and develop additional product candidates. We may not be successful in our efforts to develop bezuclastinib or expand our pipeline of drug candidates36% rewritten
2. 02We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively50% rewritten
3. 03The commercial success of any future approved drugs, including bezuclastinib, will depend upon the degree of market acceptance by physicians, patients, third-party payors, and others in the medical community
4. 04The insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for bezuclastinib or any of our other product candidates could limit our ability to market those products and decrease our ability to generate revenueNew
5. 05A variety of risks associated with marketing our product candidates internationally could materially adversely affect our business52% rewritten
6. 06If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of bezuclastinib or any of our other product candidatesNew
7. 07Information obtained from expanded access studies may not reliably predict the efficacy of our future product candidates in company-sponsored clinical trials and may lead to adverse events that could limit approval
8. 08Clinical trials are expensive, time-consuming, and difficult to design and implement
9. 09If unacceptable side effects are identified during the development of our drug candidates, we may need to abandon or limit such development
10. 10If difficulties arise enrolling patients in our clinical trials, clinical development activities could be delayed or otherwise adversely affected51% rewritten
11. 11Since the number of patients that we have dosed to date in some of our clinical trials is small, the results from such clinical trials may be less reliable than results achieved in larger clinical trials53% rewritten
12. 12We may choose not to develop a potential product candidate, or we may suspend, deprioritize or terminate one or more discovery programs or preclinical or clinical product candidates or programs
13. 13We may form or seek collaborations or strategic alliances or enter into additional licensing arrangements in the future, but we may not realize any resulting benefits

Risks Related to Our Reliance on Third Parties

1. 14The third parties upon whom we rely for the supply of the API and drug product used in bezuclastinib are our sole source of supply, and the loss of any of these suppliers could significantly harm our business

Risks Related to Regulatory Approval of Our Drug Candidates and Other Legal Compliance Matters

1. 15Breakthrough Therapy Designation for bezuclastinib and our other product candidates or participation in the FDA’s Real-Time Oncology Review (“RTOR”) program may not lead to a faster development or review processNew
2. 16The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates
3. 17We may seek priority review designation for one or more of our product candidates, but we might not receive such designation, and even if we do, such designation may not lead to faster development or regulatory review or approval processNew
4. 18Regulatory authorities, including the FDA, may disagree with our regulatory plan and we may fail to obtain regulatory approval of our product candidates33% rewritten
5. 19Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions
6. 20Evolving regulatory standards, including as a result of changes in government leadership, make it difficult to accurately predict the likelihood of marketing approval even when clinical trials meet their endpointsNew
7. 21Even if we receive regulatory approval for any investigational product, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expenseNew
8. 22The occurrence of any event or penalty described above may inhibit our ability to commercialize our investigational products and generate revenue and could require us to expend significant time and resources in response and could generate negative publicityNew
9. 23Pharmaceutical and biological product marketing is subject to substantial regulation in the United States. and any failure by us or our commercial and collaborative partners to comply with applicable statutes or regulations can adversely affect our business
10. 24The impact of healthcare legislation and other changes in the healthcare industry and in healthcare spending on us is currently unknown, and may adversely affect our business model36% rewritten
11. 25Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
12. 26We face potential liability related to the privacy of health information we obtain from clinical trials sponsored by us
13. 27If we are unable to successfully develop companion diagnostic tests for our drug candidates that require such tests, or experience significant delays in doing so, we may not realize the full commercial potential of these drug candidates
14. 28We may not be able to file investigational new drug applications (“IND”s) or IND amendments or clinical trial authorization applications (“CTA”s) to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA or other regulatory authorities may not permit us to proceed

Risks Related to Our Intellectual Property

1. 29If our efforts to protect the proprietary nature of the intellectual property related to our technologies are not adequate, we may not be able to compete effectively in our market
2. 30We depend on intellectual property licensed from third parties and termination of any of these licenses could result in the loss of significant rights, which would harm our business
3. 31We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses
4. 32Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts
5. 33We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful
6. 34Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court or the USPTO
7. 35Patent terms may be inadequate to protect our competitive position on our product candidates and any future products for an adequate amount of time
8. 36Changes to patent law in the United States and in foreign jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates and future products
9. 37We may not be able to seek or obtain patent protection throughout the world or enforce such patent protection once obtained
10. 38If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our trademarks of interest and our business may be adversely affected

Risks Related to Employee Matters and Managing Growth

1. 39We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy
2. 40We have experienced significant growth and expect to continue to expand our company to support research, development and commercial capabilities and may face challenges in managing our growthNew
3. 41To market bezuclastinib or any approved product candidate in the future, we must continue building our sales, marketing, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, as we do not presently have all of these capabilitiesNew
4. 42our direct or indirect sales and marketing efforts may not be successful; andNew
5. 43Our business and operations could suffer in the event of system failures or unauthorized or inappropriate use of or access to our systems

Risks Related to Our Financial Position and Need for Additional Capital

1. 44We have incurred net losses in every year since our inception and anticipate that we will continue to incur net losses in the future
2. 45our ability to avoid third-party patent interference, intellectual property challenges or intellectual property infringement claims28% rewritten
3. 46We may require additional capital to finance our planned operations. If we fail to obtain additional financing when needed, or on attractive terms, we may be unable to complete the development and commercialization of our product candidates30% rewritten
4. 47Our ability to use net operating losses and tax credit carryforwards to offset future taxable income may be subject to certain limitations27% rewritten
5. 48We may be subject to adverse legislative or regulatory tax changes that could negatively impact our financial condition

Risks Related to Ownership of our Common Stock

1. 49The price of our stock may be volatile, and you could lose all or part of your investment
2. 50Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant influence over matters subject to stockholder approval
3. 51An active trading market for our common stock may not be sustained
4. 52Future sales and issuances of our common stock or rights to purchase common stock could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall
5. 53Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control, which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management

Risks Related to our Convertible Notes

1. 54Our indebtedness and liabilities could limit the cash flow available for our operations, expose us to risks that could adversely affect our business, financial condition and results of operations and impair our ability to satisfy our obligations under the notesNew
2. 55make an acquisition of our company less attractive or more difficultNew
3. 56We may be unable to raise the funds necessary to repurchase the Notes for cash following a fundamental change or to pay any cash amounts due upon maturity or conversion of the NotesNew
4. 57The conditional conversion feature of the Notes, if triggered, may adversely affect our financial condition and results of operationsNew
5. 58Transactions relating to the Notes may affect the value of our common stockNew
6. 59The accounting method for reflecting the Notes on our consolidated balance sheet, accruing interest expense for the Notes and reflecting the underlying shares of our common stock in our reported diluted earnings per share may adversely affect our reported earnings and financial conditionNew
7. 60The conversion of the Notes could impair our financial position and liquidityNew